Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines

References

• Banchereau J, Steinmann RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–252.
   PubMed Web of Science ®Google Scholar
• Engelhard VH. Structure of peptides associated with MHC class I molecules. Curr Opin Immunol. 1994;6(1):13–23.
   PubMed Web of Science ®Google Scholar
• Rötzschke O, Falk K. Origin, structure and motifs of naturally processed MHC class II ligands. Curr Opin Immunol. 1994;6(1):45–51.
   PubMed Web of Science ®Google Scholar
• Weiss RA, Clapham PR, Cheingsong-Popov R, et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 1985;316(6023):69–72.
   PubMed Web of Science ®Google Scholar
• Lyerly HK, Reed DL, Matthews TJ, et al. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses. 1987;3(4):409–422.
   PubMed Web of Science ®Google Scholar
• Berman PW, Gregory TJ, Riddle L, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990;345(6276):622–625.
   PubMed Web of Science ®Google Scholar
• Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1996;173(2):340–348.
   PubMed Web of Science ®Google Scholar
• Wong-Staal F, Shaw GM, Hahn BH, et al. Genomic diversity of human T-lymphotropic virus type III (HTLV-III). Science. 1985;229(4715):759–762.
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M, Reitz MS Jr, Robey WG, et al. In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol. 1986;137:3306–3309.
   PubMed Web of Science ®Google Scholar
• Berman PW, Groopman JE, Gregory T, et al. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 1988;85(14):5200–5204.
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM, Welsh RM. H-2 compatibility requirement for virus-specific T cell-mediated effector functions in vivo. I. Specificity of T cells conferring antiviral protection against lymphocytic choriomeningitis virus is associated with H-2K and H-2D. J Immunol. 1976;117(5 Pt 1):1495–1502.
   PubMed Web of Science ®Google Scholar
• Baba TW, Liska V, Khimani AH, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med. 1999;5(2):194–203.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Barouch DH, Baden LR. Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS. 2013;8(5):412–420.
   PubMed Web of Science ®Google Scholar
• Parks CL, Picker LJ, King CR. Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS. 2013;8(5):402–411.
   PubMed Web of Science ®Google Scholar
• Ramirez LA, Arango T, Boyer J. Therapeutic and prophylactic DNA vaccines for HIV-1. Expert Opin Biol Ther. 2013;13(4):563–573.
   PubMed Web of Science ®Google Scholar
• Townsend AR, Rothbard J, Gotch FM, et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 1986;44(6):959–968.
   PubMed Web of Science ®Google Scholar
• Aichele P, Hengartner H, Zinkernagel RM, et al. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med. 1990;171(5):1815–1820.
   PubMed Web of Science ®Google Scholar
• Hart MK, Weinhold KJ, Scearce RM, et al. Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc Natl Acad Sci U S A. 1991;88(21):9448–9452.
   PubMed Web of Science ®Google Scholar
• Schulz M, Zinkernagel RM, Hengartner H. Peptide-induced antiviral protection by cytotoxic T cells. Proc Natl Acad Sci U S A. 1991;88(3):991–993.
   PubMed Web of Science ®Google Scholar
• Wm K, Roux L, Curren J, et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A. 1991;88(6):2283–2287.
   PubMed Web of Science ®Google Scholar
• Melchers F, Braun V, Galanos C. The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen. J Exp Med. 1975;142(2):473–482.
   PubMed Web of Science ®Google Scholar
• Johnson RB, Köhl S, Wiesmüller K, et al. Synthetic analogues of the N-terminal lipid part of bacterial lipoprotein are B-lymphocyte mitogens in vitro and in vivo. Immunobiology. 1983;165(1):27–35.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Heinle S, Schade UF, et al. Stimulation of human and murine adherent cells by bacterial lipoprotein and synthetic lipopeptide analogues. Immunobiology. 1988;177(2):158–170.
   PubMed Web of Science ®Google Scholar
• Wiesmüller KH, Jung G, Hess G. Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine. 1989;7(1):29–33.
   PubMed Web of Science ®Google Scholar
• Deres K, Schild H, Wiesmüller KH, et al. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 1989;342(6249):561–564.
   PubMed Web of Science ®Google Scholar
• Zeng W, Ghosh S, Lau YF, et al. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol. 2002;169(9):4905–4912.
   PubMed Web of Science ®Google Scholar
• Jackson DC, Lau YF, Le T, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A. 2004;101(43):15440–15445.
   PubMed Web of Science ®Google Scholar
• Coon J, Hunter R. Selective induction of delayed hypersensitivity by a lipid conjugated protein antigen which is localized in thymus dependent lymphoid tissue. J Immunol. 1973;110(1):183–190.
   PubMed Web of Science ®Google Scholar
• Dailey MO, Post W, Hunter RL. Induction of cell-mediated immunity to chemically modified antigens in guinea pigs. II. The interaction between lipid-conjugated antigens, macrophages, and T lymphocytes. J Immunol. 1977;118(3):963–970.
   PubMed Web of Science ®Google Scholar
• Hopp TP. Immunogenicity of a synthetic HBsAg peptide: enhancement by conjugation to a fatty acid carrier. Mol Immunol. 1984;21(1):13–16.
   PubMed Web of Science ®Google Scholar
• Robinson JH, Case MC, Brooks CG. Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells. Immunology. 1992;76(4):593–598.
   PubMed Web of Science ®Google Scholar
• Uhl B, Wolf B, Schwinde A, et al. Intracellular localization of a lipopeptide macrophage activator: immunocytochemical investigations and EELS analysis on ultrathin cryosections of bone marrow-derived macrophages. J Leukoc Biol. 1991;50(1):10–18.
   PubMed Web of Science ®Google Scholar
• Schild H, Deres K, Wiesmüller KH, et al. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol. 1991;21(11):2649–2654.
   PubMed Web of Science ®Google Scholar
• Falo LD Jr, Colarusso LJ, Benacerraf B, et al. Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc Natl Acad Sci U S A. 1992;89(17):8347–8350.
   PubMed Web of Science ®Google Scholar
• Rouaix F, Gras-Masse H, Mazingue C, et al. Effect of a lipopeptidic formulation on macrophage activation and peptide presentation to T cells. Vaccine. 1994;12(13):1209–1214.
   PubMed Web of Science ®Google Scholar
• Tsunoda I, Sette A, Fujinami RS, et al. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine. 1999;17(7–8):675–685.
   PubMed Web of Science ®Google Scholar
• Loing E, Andrieu M, Thiam K, et al. Extension of HLA-A*0201-restricted minimal epitope by N epsilon-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells. J Immunol. 2000;164(2):900–907.
   PubMed Web of Science ®Google Scholar
• Andrieu M, Loing E, Desoutter JF, et al. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation. Eur J Immunol. 2000;30(11):3256–3265.
   PubMed Web of Science ®Google Scholar
• Andrieu M, Desoutter JF, Loing E, et al. Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol. 2003;77(2):1564–1570.
   PubMed Web of Science ®Google Scholar
• Seifert U, Marañón C, Shmueli A, et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol. 2003;4(4):375–379.
   PubMed Web of Science ®Google Scholar
• Hoeffel G, Ripoche AC, Matheoud D, et al. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity. 2007;27(3):481–492.
   PubMed Web of Science ®Google Scholar
• Song YC, Chou AH, Homhuan A, et al. Presentation of lipopeptide by dendritic cells induces anti-tumor responses via an endocytosis-independent pathway in vivo. J Leukoc Biol. 2011;90(2):323–332.
   PubMed Web of Science ®Google Scholar
• Pfender NA, Grosch S, Roussel G, et al. Route of uptake of palmitoylated encephalitogenic peptides of myelin proteolipid protein by antigen-presenting cells: importance of the type of bond between lipid chain and peptide and relevance to autoimmunity. J Immunol. 2008;180(3):1398–1404.
   PubMed Web of Science ®Google Scholar
• Stittelaar KJ, Hoogerhout P, Ova W, et al. In vitro processing and presentation of a lipidated cytotoxic T-cell epitope derived from measles virus fusion protein. Vaccine. 2001;20(1–2):249–261.
   PubMed Web of Science ®Google Scholar
• Verheul AF, Udhayakumar V, Jue DL, et al. Monopalmitic acid-peptide conjugates induce cytotoxic T cell responses against malarial epitopes: importance of spacer amino acids. J Immunol Methods. 1995;182(2):219–226.
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388(6640):394–397.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637–650.
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Tel J, Sliepen KH, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother. 2010;59(10):1573–1582.
   PubMed Web of Science ®Google Scholar
• Hertz CJ, Kiertscher SM, Godowski PJ, et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol. 2001;166(4):2444–2450.
   PubMed Web of Science ®Google Scholar
• Zhu X, Ramos TV, Gras-Masse H, et al. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol. 2004;34(11):3102–3114.
   PubMed Web of Science ®Google Scholar
• Martinon F, Gras-Masse H, Boutillon C, et al. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J Immunol. 1992;149(10):3416–3422.
   PubMed Web of Science ®Google Scholar
• Bourgault I, Chirat F, Tartar A, et al. Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG- or NEF-specific cytotoxic T lymphocytes by lipopeptides. J Immunol. 1994;152(5):2530–2537.
   PubMed Web of Science ®Google Scholar
• Villada IB, Mortara L, Aubertin AM, et al. Positive role of macaque cytotoxic T lymphocytes during SIV infection: decrease of cellular viremia and increase of asymptomatic clinical period. FEMS Immunol Med Microbiol. 1997;19(1):81–87.
   PubMedGoogle Scholar
• Sauzet JP, Déprez B, Martinon F, et al. Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine. 1995;13(14):1339–1345.
   PubMed Web of Science ®Google Scholar
• Gras-Masse H. Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations. Mol Immunol. 2001;38(6):423–431.
   PubMed Web of Science ®Google Scholar
• Deprez B, Sauzet JP, Boutillon C, et al. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine. 1996;14(5):375–382.
   PubMed Web of Science ®Google Scholar
• Mortara L, Letourneur F, Gras-Masse H, et al. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J Virol. 1998;72(2):1403–1410.
   PubMed Web of Science ®Google Scholar
• Panina-Bordignon P, Tan A, Termijtelen A, et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol. 1989;19(12):2237–2242.
   PubMed Web of Science ®Google Scholar
• Mortara L, Gras-Masse H, Rommens C, et al. Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J Virol. 1999;73(5):4447–4451.
   PubMed Web of Science ®Google Scholar
• Villefroy P, Letourneur F, Coutsinos Z, et al. SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251. Virol J. 2006;3:65.
   PubMed Web of Science ®Google Scholar
• Salmon-Céron D, Durier C, Desaint C, et al. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. Aids. 2010;24(14):2211–2223.
   PubMed Web of Science ®Google Scholar
• Dereuddre-Bosquet N, Baron ML, Contreras V, et al. HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015;33(20):2354–2359.
   PubMed Web of Science ®Google Scholar
• Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987;328(6128):345–348.
   PubMed Web of Science ®Google Scholar
• Walker BD, Flexner C, Paradis TJ, et al. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science. 1988;240(4848):64–66.
   PubMedGoogle Scholar
• Chenciner N, Michel F, Dadaglio G, et al. Multiple subsets of HIV-specific cytotoxic T lymphocytes in humans and in mice. Eur J Immunol. 1989;19(9):1537–1544.
   PubMed Web of Science ®Google Scholar
• Bouillot M, Choppin J, Cornille F, et al. Physical association between MHC class I molecules and immunogenic peptides. Nature. 1989;339(6224):473–475.
   PubMed Web of Science ®Google Scholar
• Choppin J, Martinon F, Gomard E, et al. Analysis of physical interactions between peptides and HLA molecules and application to the detection of human immunodeficiency virus 1 antigenic peptides. J Exp Med. 1990;172(3):889–899.
   PubMed Web of Science ®Google Scholar
• Choppin J, Martinon F, Connan F, et al. HLA-binding regions of HIV-1 proteins. I. Detection of seven HLA binding regions in the HIV-1 Nef protein. J Immunol. 1991;147(2):569–574.
   PubMed Web of Science ®Google Scholar
• Choppin J, Martinon F, Connan F, et al. HLA-binding regions of HIV-1 proteins. II. A systematic study of viral proteins. J Immunol. 1991;147(2):575–583.
   PubMed Web of Science ®Google Scholar
• Culmann-Penciolelli B, Lamhamedi-Cherradi S, Couillin I, et al. Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein. J Virol. 1994;68(11):7336–7343.
   PubMed Web of Science ®Google Scholar
• Couillin I, Culmann-Penciolelli B, Gomard E, et al. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein. J Exp Med. 1994;180(3):1129–1134.
   PubMed Web of Science ®Google Scholar
• Buseyne F, McChesney M, Porrot F, et al. Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: gag epitopes are clustered in three regions of the p24gag protein. J Virol. 1993;67(2):694–702.
   PubMed Web of Science ®Google Scholar
• Choppin J, Cohen W, Bianco A, et al. Characteristics of HIV-1 Nef regions containing multiple CD8+ T cell epitopes: wealth of HLA-binding motifs and sensitivity to proteasome degradation. J Immunol. 2001;166(10):6164–6169.
   PubMed Web of Science ®Google Scholar
• Nixon DF, Townsend AR, Elvin JG, et al. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature. 1988;336(6198):484–487.
   PubMed Web of Science ®Google Scholar
• Wahren B, Rosen J, Sandström E, et al. HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J Acquir Immune Defic Syndr. 1989;2(5):448–456.
   PubMed Web of Science ®Google Scholar
• Johnson RP, Trocha A, Yang L, et al. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol. 1991;147(5):1512–1521.
   PubMed Web of Science ®Google Scholar
• Lucchiari-Hartz M, Van Endert PM, Lauvau G, et al. Cytotoxic T lymphocyte epitopes of HIV-1 Nef: generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J Exp Med. 2000;191(2):239–252.
   PubMed Web of Science ®Google Scholar
• Wilson CC, Palmer B, Southwood S, et al. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol. 2001;75(9):4195–4207.
   PubMed Web of Science ®Google Scholar
• Kaufmann DE, Bailey PM, Sidney J, et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol. 2004;78(9):4463–4477.
   PubMed Web of Science ®Google Scholar
• Pancré V, Delhem N, Yazdanpanah Y, et al. Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection. Vaccine. 2007;25(31):5927–5937.
   PubMed Web of Science ®Google Scholar
• Buggert M, Norström MM, Czarnecki C, et al. Characterization of HIV-specific CD4+ T cell responses against peptides selected with broad population and pathogen coverage. PLoS One. 2012;7(7):e39874.
   PubMed Web of Science ®Google Scholar
• Ranasinghe S, Flanders M, Cutler S, et al. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol. 2012;86(1):277–283.
   PubMed Web of Science ®Google Scholar
• Schieffer M, Jessen HK, Oster AF, et al. Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control. J Virol. 2014;88(13):7357–7366.
   PubMed Web of Science ®Google Scholar
• Pérez CL, Larsen MV, Gustafsson R, et al. Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. J Immunol. 2008;180(7):5092–5100.
   PubMed Web of Science ®Google Scholar
• Streeck H, Jolin JS, Qi Y, et al. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol. 2009;83(15):7641–7648.
   PubMed Web of Science ®Google Scholar
• Hertz T, Ahmed H, Friedrich DP, et al. HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog. 2013;9(6):e1003404.
   PubMed Web of Science ®Google Scholar
• Inwoley A, Recordon-Pinson P, Dupuis M, et al. Cross-clade conservation of HIV type 1 Nef immunodominant regions recognized by CD8+ T cells of HIV type 1 CRF02_AG-infected Ivorian (West Africa). AIDS Res Hum Retroviruses. 2005;21(7):620–628.
   PubMed Web of Science ®Google Scholar
• Daubersies P, Thomas AW, Millet P, et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med. 2000;6(11):1258–1263.
   PubMed Web of Science ®Google Scholar
• Le Gal FA, Prevost-Blondel A, Lengagne R, et al. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study. Int J Cancer. 2002;98(2):221–227.
   PubMed Web of Science ®Google Scholar
• Bettahi I, Nesburn AB, Yoon S, et al. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest Ophthalmol Vis Sci. 2007;48(10):4643–4653.
   PubMed Web of Science ®Google Scholar
• Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res. 1998;4(9):2103–2109.
   PubMed Web of Science ®Google Scholar
• Xu DH, Zhou CH, Xia YP, et al. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer. Acta Pharmacol Sin. 2007;28(5):695–702.
   PubMed Web of Science ®Google Scholar
• Livingston BD, Crimi C, Grey H, et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol. 1997;159(3):1383–1392.
   PubMed Web of Science ®Google Scholar
• Diamond DJ, York J, Sun JY, et al. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 1997;90(5):1751–1767.
   PubMed Web of Science ®Google Scholar
• Chua BY, Eriksson EM, Brown LE, et al. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine. 2008;26(37):4866–4875.
   PubMed Web of Science ®Google Scholar
• Alphs HH, Gambhira R, Karanam B, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A. 2008;105(15):5850–5855.
   PubMed Web of Science ®Google Scholar
• Pejoski D, Zeng W, Rockman S, et al. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol. 2010l;88(5):605–611.
   PubMed Web of Science ®Google Scholar
• Klinguer C, David D, Kouach M, et al. Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate. Vaccine. 1999;18(3–4):259–267.
   PubMed Web of Science ®Google Scholar
• Gahéry-Ségard H, Pialoux G, Charmeteau B, et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol. 2000;74(4):1694–1703.
   PubMed Web of Science ®Google Scholar
• Pialoux G, Gahéry-Ségard H, Sermet S, et al. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. Aids. 2001;15(10):1239–1249.
   PubMed Web of Science ®Google Scholar
• Gahéry-Ségard H, Pialoux G, Figueiredo S, et al. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J Virol. 2003;77(20):11220–11231.
   PubMed Web of Science ®Google Scholar
• Gahery H, Figueiredo S, Texier C, et al. HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+/CD8+ T cells in humans after lipopeptide vaccination. AIDS Res Hum Retroviruses. 2007;23(3):427–437.
   PubMed Web of Science ®Google Scholar
• Launay O, Durier C, Desaint C, et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS One. 2007;2(8):e725.
   PubMed Web of Science ®Google Scholar
• Launay O, Surenaud M, Desaint C, et al. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013;31(40):4406–4415.
   PubMed Web of Science ®Google Scholar
• Frey SE, Peiperl L, McElrath MJ, et al. Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. Clin Vaccine Immunol. 2014;21(11):1589–1599.
   PubMed Web of Science ®Google Scholar
• Keating SM, Bejon P, Berthoud T, et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol. 2005;175(9):5675–5680.
   PubMed Web of Science ®Google Scholar
• Richert L, Hue S, Hocini H, et al. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. Aids. 2013;27(9):1421–1431.
   PubMed Web of Science ®Google Scholar
• Richert L, Doussau A, Lelièvre JD, et al. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials. 2014;15:68.
   PubMed Web of Science ®Google Scholar
• Brandler S, Lepelley A, Desdouits M, et al. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. J Virol. 2010;84(10):5314–5328.
   PubMed Web of Science ®Google Scholar
• Blazevic V, Männik A, Malm M, et al. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine. AIDS Res Hum Retroviruses. 2006;22(7):667–677.
   PubMed Web of Science ®Google Scholar
• Lelièvre JD, Lacabaratz C, Wiedemann A, et al. Immunogenicity and safety of 4 prime-boost combinations of HIV vaccine candidates (MVAHIV-B; LIPO-5; GTU-MultiHIV B) in healthy volunteers - ANRS/INSERM VRI01 phase I/II randomized trial. In: Poster session presented at: 9th IAS Conference on HIV Science; 2017 Jul 23-26; Paris.
   Google Scholar
• Seth A, Yasutomi Y, Jacoby H, et al. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses. 2000;16(4):337–343.
   PubMed Web of Science ®Google Scholar
• Gahery H, Daniel N, Charmeteau B, et al. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res Hum Retroviruses. 2006;22(7):684–694.
   PubMed Web of Science ®Google Scholar
• Pialoux G, Quercia RP, Gahery H, et al. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study. Clin Vaccine Immunol. 2008;15(3):562–568.
   PubMed Web of Science ®Google Scholar
• Lévy Y, Gahéry-Ségard H, Durier C, et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. Aids. 2005;19(3):279–286.
   PubMed Web of Science ®Google Scholar
• Lévy Y, Durier C, Lascaux AS, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. Aids. 2006;20(3):405–413.
   PubMed Web of Science ®Google Scholar
• Goujard C, Marcellin F, Hendel-Chavez H, et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res Hum Retroviruses. 2007;23(9):1105–1113.
   PubMed Web of Science ®Google Scholar
• Moir S, Buckner CM, Ho J, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 2010;116(25):5571–5579.
   PubMed Web of Science ®Google Scholar
• Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000;97(7):3382–3387.
   PubMed Web of Science ®Google Scholar
• Pollard RB, Rockstroh JK, Pantaleo G, et al. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2014;14(4):291–300.
   PubMed Web of Science ®Google Scholar
• Boffito M, Fox J, Bowman C, et al. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial. Vaccine. 2013;31(48):5680–5686.
   PubMed Web of Science ®Google Scholar
• Borthwick N, Ahmed T, Ondondo B, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther. 2014;22(2):464–475.
   PubMed Web of Science ®Google Scholar
• Rosario M, Borthwick N, Stewart-Jones GB, et al. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. Aids. 2012;26(3):275–284.
   PubMed Web of Science ®Google Scholar
• Reguzova A, Antonets D, Karpenko L, et al. Design and evaluation of optimized artificial HIV-1 poly-T cell-epitope immunogens. PLoS One. 2015;10(3):e0116412.
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Fay JW, et al. Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 2007;220:129–150.
   PubMed Web of Science ®Google Scholar
• García F, Routy JP. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine. 2011;29(38):6454–6463.
   PubMed Web of Science ®Google Scholar
• Carbonneil C, Aouba A, Burgard M, et al. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8 T cells. AIDS. 2003;17(12):1731–1740.
   PubMed Web of Science ®Google Scholar
• Cobb A, Roberts LK, Palucka AK, et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Methods. 2011;365(1–2):27–37.
   PubMed Web of Science ®Google Scholar
• Lévy Y, Thiébaut R, Montes M, et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. Eur J Immunol. 2014;44(9):2802–2810.
   PubMed Web of Science ®Google Scholar
• Brezar V, Ruffin N, Richert L, et al. Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity. PLoS Pathog. 2015;11(3):e1004752.
   PubMed Web of Science ®Google Scholar
• Yin W, Gorvel L, Zurawski S, et al. Functional specialty of CD40 and dendritic cell surface lectins for exogenous antigen presentation to CD8(+) and CD4(+) T cells. EBioMedicine. 2016;5:46–58.
   PubMed Web of Science ®Google Scholar
• Flamar AL, Contreras V, Zurawski S, et al. Delivering HIV Gagp24 to DCIR induces strong antibody responses in vivo. PLoS One. 2015;10(9):e0135513.
   PubMed Web of Science ®Google Scholar
• Zurawski G, Zurawski S, Flamar AL, et al. Targeting HIV-1 Env gp140 to LOX-1 elicits immune responses in Rhesus Macaques. PLoS One. 2016;11(4):e0153484.
   PubMed Web of Science ®Google Scholar
• Zurawski G, Shen X, Zurawski S, et al. Superiority in Rhesus Macaques of targeting HIV-1 Env Gp140 to CD40 Versus LOX-1 in combination with replication competent NYVAC-KC for induction of Env-specific antibody and T cell responses. J Virol. 2017 Feb 15:pii: JVI.01596-16. [Epub ahead of print]. DOI:10.1128/JVI.01596-16.
   PubMed Web of Science ®Google Scholar
• Lévy Y, Zurawski S, Flamar AL, et al. Vaccines for therapeutic cellular immunity that target HIV Gag, Pol, and Nef epitopes to CD40 and DCIR elicit T cell responses in Rhesus Macaques. In: Poster session presented at: HIV Research for Prevention (R4P); 2014 Oct 28–31; Cape Town.
   Google Scholar
• Flamar AL, Xue Y, Zurawski SM, et al. Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. Aids. 2013;27(13):2041–2051.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–2220.
   PubMed Web of Science ®Google Scholar
• McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372(9653):1894–1905.
   PubMed Web of Science ®Google Scholar
• Janes HE, Cohen KW, Frahm N, et al. Higher T-cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial. J Infect Dis. 2017;215(9):1376–1385.
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Picker LJ. Unusual antigen presentation offers new insight into HIV vaccine design. Curr Opin Immunol. 2017;46:75–81.
   PubMed Web of Science ®Google Scholar
• Durier C, Launay O, Meiffrédy V, et al. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. Aids. 2006;20(7):1039–1049.
   PubMed Web of Science ®Google Scholar
• Pialoux G, Hocini H, Pérusat S, et al. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study. Vaccine. 2008;26(21):2657–2666.
   PubMed Web of Science ®Google Scholar
• BenMohamed L, Krishnan R, Auge C, et al. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology. 2002;106(1):113–121.
   PubMed Web of Science ®Google Scholar
• Deliyannis G, Kedzierska K, Lau YF, et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol. 2006;36(3):770–778.
   PubMed Web of Science ®Google Scholar
• BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines–yesterday, today, and tomorrow. Lancet Infect Dis. 2002;2(7):425–431.
   PubMed Web of Science ®Google Scholar
• Zhang X, Dervillez X, Chentoufi AA, et al. Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88. J Immunol. 2012;189(9):4496–4509.
   PubMed Web of Science ®Google Scholar
• Figueiredo S, Charmeteau B, Surenaud M, et al. Memory CD8(+) T cells elicited by HIV-1 lipopeptide vaccines display similar phenotypic profiles but differences in term of magnitude and multifunctionality compared with FLU- or EBV-specific memory T cells in humans. Vaccine. 2014;32(4):492–501.
   PubMed Web of Science ®Google Scholar
• Liu R, Wang J, Yang Y, et al. A novel rabies virus lipopeptide provides a better protection by improving the magnitude of DCs activation and T cell responses. Virus Res. 2016;221:66–73.
   PubMed Web of Science ®Google Scholar